alpha-aminopyridine has been researched along with Polycystic Ovarian Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Janez, A; Jensterle, M; Kocjan, T | 1 |
| Janez, A; Jensterle, M; Kocjan, T; Salamun, V; Vrtacnik Bokal, E | 1 |
2 trial(s) available for alpha-aminopyridine and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome.
Topics: Adult; Aminopyridines; Benzamides; Body Weight; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Insulin; Menstrual Cycle; Metformin; Molecular Targeted Therapy; Obesity; Phosphodiesterase 4 Inhibitors; Polycystic Ovary Syndrome; Sex Hormone-Binding Globulin; Testosterone | 2014 |
Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.
Topics: Adult; Aminopyridines; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Female; Glucagon-Like Peptide-1 Receptor; Humans; Liraglutide; Metformin; Obesity; Phosphodiesterase 4 Inhibitors; Polycystic Ovary Syndrome; Weight Loss | 2015 |